AbCellera Biologics Quarterly Balance Sheet
NASDAQ: ABCLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AbCellera Biologics financial position
As of Jun 30, 2026, AbCellera Biologics reported total assets of $1.31 billion, down 6.7% from a year earlier against total liabilities of $411.6 million. Shareholders' equity stood at $896.0 million, or 68.5% of assets. The company held $120.1 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 12.77, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
AbCellera Biologics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 120.06M | 77.06M | 128.51M | 83.16M | 92.44M | 159.27M | 156.32M | 126.64M | 148.31M | 123.57M | 133.32M | 172.42M |
| Receivables | 38.42M | 39.16M | 39.41M | 71.25M | 70.00M | 63.61M | 31.98M | — | — | — | 0 | — |
| Inventory | 7.58M | 7.86M | 6.34M | — | — | — | 0 | — | — | — | — | — |
| Total Current Assets | 679.23M | 664.60M | 728.23M | 695.14M | 742.14M | 764.98M | 751.37M | 742.88M | 771.55M | 813.95M | 871.99M | 919.52M |
| Property, Plant & Equipment | — | — | — | — | — | — | — | — | — | — | — | 277.21M |
| Goodwill | 47.81M | 47.81M | 47.81M | 47.81M | 47.81M | 47.81M | 47.81M | 47.81M | 47.81M | 47.81M | 47.81M | 47.81M |
| Intangible Assets | 36.53M | 37.46M | 38.38M | 39.32M | 40.26M | 41.19M | 42.11M | 52.58M | 85.66M | 118.74M | 120.42M | 124.08M |
| Total Assets | 1.31B | 1.31B | 1.36B | 1.36B | 1.40B | 1.34B | 1.36B | 1.39B | 1.41B | 1.46B | 1.49B | 1.51B |
| Accounts Payable | 12.11M | 20.81M | 25.23M | 31.77M | 32.04M | 32.80M | 34.35M | 34.80M | 26.59M | 26.91M | 28.60M | 17.43M |
| Total Current Liabilities | 53.19M | 47.29M | 64.31M | 68.80M | 67.02M | 75.40M | 76.61M | 79.57M | 70.38M | 104.88M | 119.01M | 110.24M |
| Total Liabilities | 411.56M | 369.03M | 390.05M | 391.95M | 394.99M | 321.23M | 304.47M | 314.73M | 301.51M | 333.18M | 335.78M | 329.42M |
| Shareholders' Equity | 896.02M | 938.08M | 966.90M | 964.04M | 1.01B | 1.02B | 1.06B | 1.08B | 1.11B | 1.13B | 1.15B | 1.18B |
| Retained Earnings | -128.07M | -72.65M | -29.48M | -20.54M | 36.58M | 71.31M | 116.93M | 151.14M | 202.25M | 239.18M | 279.79M | 326.94M |
| Net Cash (Debt) | 120.06M | 77.06M | 128.51M | 83.16M | 92.44M | 159.27M | 156.32M | 126.64M | 148.31M | 123.57M | 133.32M | 172.42M |
| Shares Outstanding | 306.47M | 303.95M | 300.60M | 299.01M | 295.76M | 295.76M | 295.76M | 290.82M | 290.82M | 290.82M | 290.82M | 286.85M |
This table shows 12 quarterly periods of AbCellera Biologics's balance sheet, from Q2 2026 back to Q3 2023, across 17 line items including cash & equivalents, receivables, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow ABCL's reporting calendar. What is a balance sheet?